Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
About this episode
Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He describes the options available for prophylaxis and how he treats the toxicities that do arise.
Get every episode summarized
Each time Oncology News Central Peer-Spectives publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Oncology News Central Peer-Spectives
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
Oncology News Central Peer-Spectives
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Trea...
Oncology News Central Peer-Spectives
“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm...
Oncology News Central Peer-Spectives
As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncert...
Oncology News Central Peer-Spectives